Aim To report retinal function outcomes after ophthalmic artery chemosurgery (OAC) for advanced retinoblastoma (RB) in eyes with minimal pretreatment retinal function. Methods For 72 advanced RB eyes with baseline electroretinograms (ERGs) indistinguishable from noise ('extinguished') or flicker ERG amplitudes <25 mV ('poor'), ERGs were obtained before OAC and at 3 months, 1 year and 2 years after OAC. Presence of baseline retinal detachments (RDs) and their subsequent resolution or persistence was also noted. Results At 3 months, 1 year and 2 years post-OAC, 'extinguished' eyes showed 9/15, 4/11 and 2/6 detectable ERGs, respectively, and 'poor' eyes showed 19/55, 14/30 and 8/18 ERGs exceeding 25 μV, respectively. Correlations between baseline and post-OAC ERGs were poor; however, good correlation (R 2 ) existed between ERGs post-OAC at 3 months and 1 year (0.749), at 3 months and 2 years (0.773) and at 1 year and 2 years (0.771). Overall, 49/70 eyes presented with RD; 29 RDs resolved 3 months post-OAC, with an average ERG change of +20.6 μV. Eyes with persistent RD had an average ERG change of −2.2 μV. No eyes underwent ≥25 μV change without RD resolution. Conclusions Minimal baseline ERGs do not preclude significant recovery of retinal function after OAC. Good correlation exists between ERG outcomes at 3 months and those at subsequent follow-ups, suggesting that ERG amplitudes at 3-month post-OAC can prognosticate longer term retinal function, and that improvement is durable. For eyes presenting with RD, RD resolution is necessary but not sufficient for significant (≥25 μV) increases in ERG amplitudes.
INTRODUCTION
Ophthalmic artery chemosurgery (OAC) was first introduced by our group 9 years ago as a method to salvage eyes with advanced retinoblastoma that were otherwise destined for enucleation. 1 The method consists of threading a microcatheter through the femoral artery and up to the orifice of the ophthalmic artery, through which chemotherapy can be injected in a localised fashion into the circulation of the eye and orbit; this precise chemotherapeutic delivery technique has proven successful in rescuing eyes with even the most extensive cases of retinoblastoma. [2] [3] [4] [5] [6] [7] OAC has proven effective in avoiding enucleation for a majority of cases. However, the concentrated delivery of chemotherapeutic drugs to the delicate structures of the retina raises the concern of OAC-induced retinal toxicity. To assess this issue in our practice, we have systematically monitored retinal function using serial ERG during examination under anaesthesia before and after OAC. We showed in our initial small-scale study on OAC that retinal function can persist, and in some cases even improve in advanced retinoblastoma eyes after treatment with OAC; 8 the possibility of improved retinal function with treatment was significant, given that retinoblastoma eyes with 'no useful vision' were historically enucleated. Other studies have shown that there may be some small variation in the extent of toxicity depending on the chemotherapeutic agent used, but these differences are small at our recommended doses, and likely clinically insignificant. 9 Although evidence shows that OAC retinal toxicity is of minimal clinical concern and that retinal function can remain preserved or improve in eyes with advanced retinoblastoma after treatment, it remains unclear how eyes with very poor baseline ERGs fare after OAC, and whether OAC can promote significant retinal recovery in these eyes with ostensibly poor long-term retinal prognosis. Moreover, the correlation of baseline, pretreatment ERGs with future post-treatment ERG outcomes is unknown, and hence the use of the poor baseline ERG as a predictor of future retinal recovery remains to be investigated. Finally, the physiological and anatomical mechanisms underlying any observed treatment-mediated recovery in ERG after treatment remain unclear.
To address these questions, we present here a comprehensive retrospective review of our experience with retinoblastoma eyes that possess extinguished or poor ERGs at baseline, and follow the trajectory of changes in these ERGs with time at 3 months, 1 year and 2 years after OAC treatment. We also follow the retinal detachment (RD) status of these eyes, and document occurrences of retinal reattachment as a possible repair mechanism underlying significant ERG recovery in these eyes.
METHODS Subjects
This study is a single centre retrospective review of 72 eyes with advanced retinoblastoma managed with OAC between May 2006 and October 2013. After Institutional Review Board approval for the retrospective review, patients with very advanced retinoblastoma were tabulated, with very advanced retinoblastoma being defined as either ReeseEllsworth Groups 'Va' or 'Vb' and ICRb Classification Groups 'D' or 'E' using the Children's Oncology Group version of the ICRb.
Electroretinography
ERG was performed during examination under anaesthesia, as part of regularly scheduled follow-up assessments. We used an adaptation of the International Society for Clinical Electrophysiology of Vision (ISCEV) standard ERG protocol to obtain ERG recordings, wherein we used the 30 Hz photopic flicker amplitude data as a highly representative surrogate for the complete ISCEV protocol, as previously described. 10 11 ERGs were recorded using ERG-jet contact lens electrodes and a Diagnosys Espion-3 electrodiagnostic system, with a hand-held ColorBurst ganzfeld stimulator. The initial ERG before OAC was compared with follow-up ERGs at 3 months, 1 year and 2 years after completion of OAC treatment. Based on statistical analysis of the ERGs of normal eyes that were recorded under anaesthesia, 30 Hz flicker responses indistinguishable from noise were considered extinguished, and those with flicker responses of 25 mV (approximately 25% of the normal value under our experimental conditions) or less were considered 'poor'.
Supplemental data
The online supplementary table provides data for eyes with detached retinas at baseline, including ERG amplitude changes at 3 months, location of tumour within the retina, total number of OAC cycles and drugs/doses used, additional local or systemic treatment and resolution or persistence of RD at 3 months after OAC.
RESULTS
For the purposes of this study, we included only patients whose ERGs at baseline before OAC treatment were 'extinguished' (indistinguishable from zero amplitude) or 'poor' (<25 μV), and recorded follow-up ERGs at scheduled visits 3 months, 1 year and 2 years after completion of OAC. A total of 72 eyes were followed; of these eyes, 16 had an extinguished ERG at baseline, and 56 had poor ERG recordings.
'Extinguished' ERG eyes
At 3 months after OAC, 15 of 16 eyes with extinguished baseline ERGs had follow-up measurements recorded. Of these 15 eyes, 9 (60%) had detectable increases in ERG amplitude, including 4 eyes that had ERG amplitudes ranging from 19 to 40 μV ( figure 1A) . Of the remaining six eyes that continued to have extinguished ERGs at 3 months, three remained extinguished at the 1-year and 2-year follow-up visits, two were enucleated before the 1-year follow-up visit and one was lost to follow-up.
Eleven eyes were available for the 1-year follow-up. The four eyes that had demonstrated appreciable increases from their extinguished baseline at the 3-month visit (19-40 μV range) continued to display robust amplitudes, ranging from 37 to 61 μV (figure 1B). Of the remaining seven eyes that continued to show extinguished amplitude by 1 year, four continued to have an extinguished response by 2 years, and three were lost to follow-up. By the 2-year follow-up visit, of six eyes that were extinguished at baseline, two had amplitudes that were detected by ERG ( figure 1C ). These two eyes already had recordable amplitudes by the 3-month follow-up visit.
'Poor' ERG eyes
Fifty-five out of 56 eyes with a 'poor' ERG baseline were evaluated at the 3-month follow-up. Of these eyes, 36 (65%) had a recordable increase in ERG amplitude compared with their baseline, 12 (22%) had a decrease from their initial amplitude to a new measurement above zero, and 7 (13%) became extinguished ( figure 1D ). Of the 36 eyes that had a recordable improvement from their baseline, 19 had an amplitude above 25 μV, including 3 with an ERG recording above 75 μV.
Thirty eyes were available for the 1-year follow up. Twentythree eyes (77%) had a recordable increase in ERG amplitude compared with their 'poor' baseline, including 14 (47%) eyes that had amplitudes above 25 μV and 2 (7%) above 75 μV ( figure  1E ). Four eyes (13%) had a decrease in ERG amplitude to a new level above zero, while three (10%) became extinguished (including two that were extinguished at the 3-month follow-up).
Eighteen eyes had ERGs recorded at the 2-year follow-up visit ( figure 1F ). Of these eyes, 12 (67%) had an increase in their amplitude from baseline, including 8 (44%) with amplitudes above 25 μV and 5 (28%) with amplitudes above 75 μV. Three eyes (17%) had a decrease to a level above zero, and three (17%) became extinguished (two of which were previously recorded as extinguished at 1 year).
Correlation between baseline and follow-up ERG amplitudes
To determine whether the baseline ERG amplitude of 'extinguished' and 'poor' eyes could be used to prognosticate future amplitudes and retinal recovery after OAC, we correlated the baseline amplitudes with the amplitudes measured at each of the follow-up visits described above (figure 2). Correlation was poor between the baseline amplitudes and those measured at 3-month, 1-year and 2-year visits, with R 2 values of 0.127, 0.108 and 0.215, respectively. Correlation between amplitudes at 3 months and 1 year after OAC, however, was more robust, with R 2 =0.749 ( figure 3A) . Likewise, correlation between the 3-month and 2-year amplitudes, as well as between the 1-year and 2-year amplitudes, remained strong with R 2 =0.771 and 0.773, respectively (figure 3B,C). These data suggest that the ERG amplitude measured at 3 months after OAC is a good predictor of ERG responses at the subsequent follow-up visits.
To control for possible improved therapeutic success of OAC with time leading to increased ERG amplitudes as a potential confounder for our data (a 'learning curve' effect), we determined whether there was a correlation between ERG amplitudes and the time at which the patient was treated. No such correlation existed for ERG amplitudes at baseline, at 3 months post-OAC, or for the changes in ERG amplitude from baseline to 3 months after treatment (R 2 =0.002, 0.019 and 0.025, respectively), confirming that no 'learning effect' was present. 
Reattachment of retinas detached at baseline
Of the 72 eyes examined, 49 (68%) presented with baseline RD. Given that ERG outcomes at 3 months after OAC represent longer term ERG outcomes well, we assessed for OAC-mediated retinal reattachment at this time point after treatment and analysed how ERG amplitude changes correlated with this anatomical recovery. Twenty-nine RDs (59%) had resolved by 3 months after initiation of OAC (figure 4); these cases did not include any eyes in which the RD was treated with retinal reattachment surgery (eg, vitrectomy, scleral buckling). Changes in ERG for these eyes included ranged from −8.1 to 78.6 μV, with nine eyes exhibiting a change equal to or above 25 μV. For the 20 eyes (41%) that had persistent RD at 3 months, the range of ERG changes varied from −15.5 to 12.8 μV (figure 4). The average ERG amplitude change for eyes with resolved RD was +20.6 μV, whereas eyes with persistent RD had a corresponding average ERG amplitude change of −2.2 μV; this difference was statistically significant ( p<0.001, Student's t-test). In 23 eyes that presented with the retina definitively in place at baseline, there were no ERG changes greater than 25 μV observed with treatment. Thus, the only eyes that exhibited ERG changes >25 μV at 3 months post-OAC were those with baseline RD that resolved with treatment. Representative images for eyes presenting with RDs, with subsequent RD resolution or persistence, are shown (figure 5).
We could not clearly identify a factor to predict whether a detached retina would reattach with OAC treatment. Patients with baseline detached retinas that eventually reattached and gained appreciable increases in ERG amplitude were on average younger (11.2 months) than those whose retinas remained persistently detached (18.0 months). However, this difference did not reach statistical significance (p=0.0756 by Student t-test). Presence of vitreous and/or subretinal seeds, two other ostensibly poor prognostic factors, also did not appear to correlate with whether detached retinas reattached with OAC treatment.
DISCUSSION
In this study, we show that in eyes with retinoblastoma, extinguished or poor retinal function before OAC does not preclude significant recovery of retinal function after the procedure, as measured by flicker ERG amplitude. While we have previously shown that persistence and recovery of retinal function was possible after OAC, our sample size was much smaller, consisting of 10 patients and with a shorter average follow-up period (3-14 months). 8 Before the use of OAC, enucleation, and thus permanent vision loss, was considered the standard of care for many of these cases. Our finding that ERG amplitudes in these 'poor starter' eyes can recover to levels that approach or equal normal retinal function establishes an additional dimension to the spectrum of recovery: in addition to patient survival, cancerfree survival and ocular survival, OAC offers the possibility of improved or restored retinal function compared with baseline as an additional measurable outcome of recovery.
Our larger sample size allows us to more precisely appraise the range of possible retinal recovery outcomes after OAC, and to correlate these final outcomes with initial pre-OAC and subsequent post-OAC ERG amplitudes. We find that there is poor correlation between the initial pre-OAC ERGs in these 'poor starters' and post-OAC ERG amplitude at 3 months, 1 year and 2 years. However, ERG amplitudes at 3 months after completion of OAC appear to correlate well with those measured at 1 year, and similarly, 1-year ERG amplitudes correlate well with those measured at 2 years. This implies that the ERG amplitudes measured at the 3-month follow-up visit are a useful indicator of retinal function to be expected in post-OAC eyes until at least 2 years after the procedure. In particular, poor ERG function at baseline is not a valid predictor of a poor retinal function outcome, and does not per se justify withholding of OAC treatment.
In this study, we also establish retinal reattachment as the anatomical mechanism underlying significant (>25 μV) changes in ERG amplitude. Occurrence of retinal reattachment with treatment thus increases the probability of a favourable outcome with regard to regaining visual function as measured by ERG in these patients who are preverbal. Conversely, persistence of a RD predicts a poor outcome with regard to increases in ERG amplitude. Based on our analysis, factors that may at first glance seem to predict a poor prognosis, such as older age or presence of vitreous seeds at time of presentation, do not predict whether a detached retina will eventually reattach with treatment, and thus the presence of these factors should not weigh into the decision to administer OAC.
While flicker ERG amplitudes provide a convenient method for measuring retinal function in patients who are preverbal, we recognise that a limitation of this study is the use of the ERG value as a surrogate for subjective visual acuity. Nevertheless, given the correlation between flicker ERG amplitude and retinal function, as well as the massive improvement in ERG amplitude that some 'poor starter' eyes undergo, these measurements may be of value in the documentation of the recovery of visual potential in any one patient.
In this study, between 23% and 35% of eyes with recordable ERGs at baseline experienced a decline in ERG amplitude over the course of treatment, depending on the time point of the observation. Possible explanations for the loss of retinal function in these eyes include toxicity of therapy to retinal tissue or to the retinal pigment epithelium (mediated by both intra-arterial and intravitreal treatment routes); retinal ischaemia, as has been noted following intra-arterial chemotherapy and suggested by thinning of the choroid as seen in previous optical coherence tomography studies;
12-14 development of RD after treatment; and possible paraneoplastic phenomena. Clarification of these effects should be an important question for further study.
While baseline ERG amplitude cannot predict the extent of recovery in a specific eye, an interesting question that remains to be answered is which characteristics contribute to retinal reattachment in some retinoblastoma eyes with extinguished or poor ERGs at baseline before OAC. Possible factors that may play into the recovery curve include duration of the detachment before treatment, retinal location of the detachments, presence and type of vitreous seeding and treatments received before OAC.
